Eng

Deep Relief

Quick links to important sections

Deep Relief

Selected form

There is no image.

Method of action: Analgesic, Antiexudative, Nonsteroidal Anti-Inflammatory

Treatment option: Ankylosing Spondylitis, Backache, Bursitis, Rheumatoid Arthritis, Spondyloarthritis, Tenosynovitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deep Relief

Quick Facts

Property	Description
Active ingredient	Ibuprofen, Levomenthol
Form	Topical Gel (Semi-solid dosage form)
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID) and Counter-irritant
General purpose	Localized anti-inflammatory action and cooling pain relief
Origin	Synthetic (Ibuprofen) and Derived Terpene Alcohol (Levomenthol)

What Type of Medicine is Deep Relief?

Deep Relief is an Over-The-Counter (OTC) combination drug formulated as a clear, non-greasy gel designed for cutaneous application. This classification as a topical preparation ensures its active components are delivered locally through the skin, concentrating the effect at the site of discomfort. Its primary pharmacological identity is a dual-action agent, combining a localized Analgesic with an Anti-inflammatory agent. The use of this dosage form is clinically recognized for targeting musculoskeletal discomfort, and this application method is a distinguishing feature, as it bypasses the systemic effects often associated with oral NSAID medications.

Understanding the Dual Active Ingredients: Ibuprofen and Levomenthol

The product’s efficacy relies on the synergistic action of its two key active ingredients: Ibuprofen and Levomenthol. Ibuprofen is identified as a synthetic Nonsteroidal Anti-Inflammatory Drug (NSAID) derived from propionic acid, widely accepted for its anti-inflammatory properties. The second component, Levomenthol, a terpene alcohol commonly used as a local anesthetic and counter-irritant, provides a sensory effect. This combination preparation is specifically positioned to offer both active tissue treatment and immediate symptomatic relief.

What is the General Purpose of This Topical Combination?

The general purpose of this topical combination is to provide focused, local pain management. A typical scenario involves the temporary relief of pain associated with minor sports injuries or strains. The Ibuprofen component’s role is to reduce underlying tissue inflammation and swelling. Concurrently, Levomenthol offers a rapid cooling sensation, serving as a counter-irritant to interrupt the transmission of pain signals. This combined approach is specifically designed to manage localized discomfort, leveraging both biochemical intervention and immediate sensory distraction.

What side effects are possible with Deep Relief?

Possible Side Effects and Safety Information

The safety profile of this topical combination preparation is defined primarily by local cutaneous reactions, which are the most frequently documented adverse effects, and a low risk of systemic complications due to limited absorption through the skin. Official safety classifications categorize adverse reactions by frequency and affected organ system.

Key Adverse Reaction Categories

SOC Classification	Example Side Effect (Frequency)
Skin and Subcutaneous Tissue Disorders	Rashes, Pruritus (itching), Urticaria (Frequent)
Immune System Disorders	Hypersensitivity reactions (e.g., Anaphylaxis) (Not Known)
Respiratory Disorders	Bronchospasm (in susceptible patients) (Less Frequent)

Systemic and Serious Safety Notes

While systemic effects are rare for this topical form, regulatory documents list serious NSAID class effects.

Serious Cutaneous Adverse Reactions (SCARs): These are Very Rare but include conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Official labeling notes that SCARs are most likely to occur within the first month of treatment.
Systemic Effects: Gastrointestinal disorders (abdominal pain, dyspepsia) and renal impairment are documented as class effects, though the incidence is lower than with oral NSAIDs.

Population-Specific Constraints

The gel is contraindicated during the third trimester of pregnancy due to risk of harm to the fetus. Caution is specifically required in patients with a history of asthma where NSAIDs may precipitate attacks, or those with pre-existing impaired renal or hepatic function. Official documents also warn that fabric that has contacted the product may burn more easily, and excessive sun exposure to the treated area should be avoided.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile is based on the systemic toxicity risks associated with the active ingredient, Ibuprofen, which occurs primarily through the accidental ingestion of the topical gel.

Overdose scope

Feature	Official Regulatory Statements
Documented overdose presentations	Gastrointestinal disturbances (epigastric pain, vomiting, diarrhea) and Central Nervous System (CNS) effects (headache, drowsiness, confusion, tinnitus, blurred vision).
Physiological systems affected	Gastrointestinal, CNS, Renal, and Cardiopulmonary systems.
When immediate medical help is required	Contact a doctor or hospital immediately if the gel is accidentally swallowed or if severe symptoms such as seizures, passing out, or trouble breathing occur.

Overdose classifications (high-level)

Feature	Official Regulatory Statements
Severity classification	Life-threatening outcomes documented include seizures, coma, acute renal failure, and severe hypotension.
Regulatory basis	Based on the established systemic toxicity profile of Ibuprofen, predominantly following accidental oral exposure.
Antidote status	No specific antidote exists; management is symptomatic and supportive treatment.

Resulting overdose structure

Overdose may present with documented clinical manifestations, including CNS disturbances and gastrointestinal distress.
Urgent medical assistance is mandated for accidental swallowing or the onset of severe, life-threatening symptoms.
Management is defined as symptomatic and supportive care, with monitoring of cardiac and vital signs required.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by detailing the spectrum of documented clinical manifestations and severe outcomes associated with systemic Ibuprofen exposure. This official risk classification mandates the immediate contact of emergency services or a hospital upon accidental ingestion or the appearance of severe symptoms.

Therapeutic Uses of Deep Relief

What Deep Relief Treats: Main Uses and Benefits

This preparation is relevant in contexts involving heightened symptomatic burden and specific therapeutic domains. It is primarily used for conditions characterized by periods of heightened symptoms, commonly used across conditions presenting with acute episodes, including those associated with physical strain and trauma. It is commonly applied in scenarios where additional management of discomfort is required, including the symptomatic relief of muscular aches, backache, joint stiffness, non-serious arthritic pain, sprains, strains, and contusions.

Quick Fact: Relief for Pain and Swelling

Feature	Therapeutic Function
Primary Action	Used for managing symptoms related to inflammatory states
Secondary Action	Provides a cooling sensation for physical discomfort
Use Context	Relevant in contexts involving acute or disruptive symptom patterns

It is relevant for managing symptom clusters that may become intense or disruptive, particularly symptoms related to inflammatory or irritative states and physical discomfort. The core therapeutic benefit may assist with managing these symptoms. This combination contributes to improved comfort during difficult episodes and may assist with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

official patient information

Eligibility and Restrictions for Use

Who can and cannot use Deep Relief?

The population eligibility for Deep Relief Topical Gel is defined by regulatory guidelines, primarily due to the presence of the Nonsteroidal Anti-inflammatory Drug (Ibuprofen).

Eligibility Scope

Regulatory Status	Population/Condition
Permitted Use	Adults and adolescents over 12 years of age
Not Recommended	Children under 12 years of age; Patients who are breastfeeding
Absolute Contraindication	Patients with known hypersensitivity to Ibuprofen, Aspirin, or any other NSAID
Absolute Contraindication	Patients in the last trimester of pregnancy (after 6 months)
Absolute Contraindication	Use on broken, damaged, or infected skin

Eligibility-Context Constraints

Certain pre-existing conditions restrict eligibility or require specific medical consultation before use, as outlined in official documentation.

NSAID-Triggered Asthma: The medicine is contraindicated in asthmatic patients in whom NSAIDs or Aspirin precipitate asthma attacks.
Comorbidities: Individuals with a history of peptic ulcer or renal impairment must seek medical advice prior to using the medicine.
Pregnancy: Use is not recommended during the first six months of pregnancy and is absolutely contraindicated in the last trimester.

The regulatory profile thus restricts use to the adult and older adolescent population without specific NSAID sensitivities or certain critical comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for this topical gel is primarily defined by its low systemic absorption, which significantly limits the potential for many systemic drug-drug interactions associated with oral medications. Official regulatory documents focus on pharmacodynamic effects and local administration restrictions.

Pharmacodynamic Interactions

Concurrent use with other oral Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin, may result in a pharmacodynamic interaction. This combination can lead to an increased incidence of adverse reactions due to the potential for additive systemic effects from combined NSAID exposure. It is noted that the specific systemic pharmacokinetic interactions—such as those involving metabolic enzymes (CYP) or drug transporters, which are common to oral ibuprofen—are officially classified as unexpected for this topical preparation under normal conditions of use.

Administration and Local Restrictions

The primary restriction imposed by the regulatory label is local. The gel must not be co-administered on the same area of skin simultaneously with any other topical medicine. This restriction is in place to manage product safety and prevent local interference. No specific interactions with food, alcohol, or herbal products are formally documented for the gel in regulatory labeling.

Mechanism of Action

Deep Relief utilizes a dual-component pharmacodynamic mechanism following topical application, targeting localized tissues. The agent Ibuprofen, a Non-Steroidal Anti-Inflammatory Drug, is absorbed percutaneously, accumulating in underlying soft tissues. At the molecular level, Ibuprofen functions as an inhibitor of the cyclooxygenase (COX) enzymes, both COX-1 and COX-2 isoforms. This inhibition decreases the conversion of arachidonic acid into pro-inflammatory prostaglandins. The consequent reduction in prostaglandin synthesis modifies local inflammatory signaling cascades and diminishes associated tissue edema. Concurrently, the agent Levomenthol acts on sensory nerve endings in the skin, functioning as an agonist at the transient receptor potential melastatin 8 (TRPM8) cold-sensitive receptor. TRPM8 activation initiates a hyperpolarization of the nerve membrane, which alters the local afferent neural signaling discharge frequency. Levomenthol also modifies the skin barrier to facilitate enhanced percutaneous delivery of Ibuprofen to the target tissue. The combined peripheral biochemical cascade modulation (Ibuprofen) and sensory afferent signal modification (Levomenthol) result in the systemic-level physiological outcome of attenuated localized nociception.

Dosage and Administration Information

The administration of Deep Relief (Ibuprofen 5% w/ w and Levomenthol 3% w/ w gel) follows a protocol for topical use. The medicine is formulated exclusively as a gel for cutaneous application. The general usage principle requires administering the lowest effective dose for the shortest possible duration, consistent with non-steroidal anti-inflammatory drug (NSAID) use.

Administration Protocol

Category	Instructions
Dosing Schedule	Apply a measured amount, typically a 1 to 4 cm strip of gel (approximately 50 to 125 mg of Ibuprofen), to the affected area per use.
Frequency and Interval	The gel may be applied up to three times daily (TID), ensuring a minimum interval of four hours between applications.
Target Population	The standard regimen is applicable to Adults, the Elderly, and adolescents over 12 years of age.

Procedural Constraints

The gel is applied as a thin layer and must be massaged gently into the skin until fully absorbed. Following application, it is required that the hands be washed immediately, unless the hands are the area being treated. A specific procedural constraint is the prohibition against covering the treated area with occlusive materials, such as plasters or bandages.

Use of the gel is restricted to a short-term course, with a maximum continuous duration of two weeks. If symptoms persist beyond this two-week limit, seeking consultation is advised.

Recent Clinical Evidence

Deep Relief: Recent Clinical Evidence

Evidence for Acute Musculoskeletal Pain and Soft-Tissue Trauma

The research base for topical treatments like Deep Relief has been established through Randomized Controlled Trials (RCTs) and systematic reviews that was evaluated in research scenarios involving acute physical discomfort. This preparation was studied for conditions associated with physical strain, such as sprains, strains, contusions, and localized muscular aches.

Research examined outcomes related to physical discomfort, including how much pain intensity changed over time. Studies monitored patient-reported outcomes describing perceived discomfort and also research examined outcomes describing time to measurable relief. These studies were generally conducted during periods of increased symptom activity in adults who had experienced recent, acute soft-tissue trauma. Findings describe patterns observed in the studies related to the time to measurable relief when compared against placebo or Ibuprofen gel-only in relevant trials.

Understanding Comparator and Sensory Effects in Studies

Research has also explored the dual formulation of Deep Relief, which combines Ibuprofen with Levomenthol. Studies included designs that directly compared the combination gel to an inactive placebo and sometimes to Ibuprofen gel alone, without the cooling agent. These trials were evaluated in contexts where researchers wanted to assess the effects of the combination. Studies explored the separate sensory component, which is the cooling sensation provided by Levomenthol. This sensory effect was observed in some studies and was included as a measured outcome alongside pain intensity changes. Comparative research helps contextualize how patients reported their experience under different research scenarios.

Study Duration and Long-Term Research

The majority of studies available for this topical gel have focused on short-term follow-up periods. This includes single-dose observational periods, sometimes lasting a few hours, to assess the initial response. Other trials involved acute treatment courses, typically monitoring responses over defined time intervals of about five to seven days. The evidence base reflects outcomes related to episodic or acute changes in symptoms.

Consequently, long-term effects are not fully established. There is limited information for long-term outcomes regarding research exploring short-term symptom changes over longer periods beyond the duration of the initial acute episodes studied in the trials. Research provides context but does not determine whether an individual will respond similarly during long-term or chronic use.

Frequently Asked Questions (FAQ)

Common questions about Deep Relief (FAQ)

Q: How is Deep Relief different from oral pain relievers?

A: According to official product information, this topical gel is designed for localized application, which results in significantly lower systemic absorption into the body compared to taking an oral NSAID (Non-Steroidal Anti-Inflammatory Drug). Due to the limited systemic absorption, the risk of systemic side effects, such as those affecting the gastrointestinal tract, is considered much lower than with oral NSAIDs. The most frequently reported undesirable effects observed are local skin reactions.

Q: What are the risks of using this gel for more than two weeks?

A: Official regulatory guidance advises using this product only for a short-term course, with a maximum continuous duration of two weeks. The risk of systemic undesirable effects, although rare with the topical form, is noted to be dependent on both the duration of treatment and the quantity of gel applied. If symptoms persist beyond the maximum continuous duration of two weeks, regulatory guidance advises seeking consultation with a healthcare professional.

Q: Can I apply a heat pack or cold pack after using the gel?

A: Regulatory information advises against covering the treated area with occlusive materials, such as plasters or bandages. While specific external therapies like heat or cold packs are not addressed, the primary restriction involves the prohibition on occluding (fully covering) the area.

Q: Is Deep Relief safe to use while breastfeeding?

A: The official product label states that use of the gel is not recommended while breastfeeding. The active ingredient, Ibuprofen, and its metabolites (breakdown products) are known to be excreted into breast milk.

Q: What is the smell of the gel caused by?

A: The unique odor and cooling sensation of the gel are caused by Levomenthol, one of its two active ingredients. Levomenthol is classified as a terpene alcohol and counter-irritant that helps relieve discomfort. This ingredient is the source of the distinctive menthol smell.

How should Deep Relief be stored and disposed of?

Storage and Disposal Requirements

Deep Relief Dual Action Pain Relief Gel must be stored according to official regulatory labeling to ensure product quality and safety.

Mandatory Storage Conditions

Detail	Requirement
Temperature	Store below 25°C.
Container	Close the cap tightly after use.
Protection	Keep out of the sight and reach of children.
Handling	Do not smoke or go near naked flames while using the product (due to fire hazard with treated fabrics).

Disposal of Unused Medicine

Any unused or expired Deep Relief gel must not be disposed of via household waste or wastewater. For safe, official disposal, users are required to take the out-of-date product to a pharmacist in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.